Cohance Lifesciences Advances ADC Strategy with $18M Investment in NJ Bio and Aruka Bio
Cohance Lifesciences Ltd 路 Others (Uncategorized) 路 04 Sept 2026, 1:23 am
Cohance Lifesciences Advances ADC Strategy with $18M Investment in NJ Bio and Aruka Bio Cohance Lifesciences will invest $18M via internal accruals to strengthen its Antibody-Drug Conjugate (ADC) capabilities. Closing by Sep'26, the deal includes a $13M outlay for 244,587 additional shares of NJ Bio at $53/share, raising Cohance's stake from 56% to 67.3%. Concurrently, Cohance will invest $5M for a 65% controlling stake in Aruka Bio, a preclinical ADC platform. The reorganization integrates NJ Bio's CRDMO services with Cohance's manufacturing, while accelerating Aruka's proprietary pipeline. Dr. Naresh Jain will serve as CEO for both subsidiaries to drive commercial alignment.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... 路 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 12 Nov 2026
- Investors Meet 路 11 Nov 2026
- Transcript of Con call 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others 路 11 Nov 2026
- Investor Presentation 路 07 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. 路 07 Nov 2026
